CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
US 简体中文
國家 • United States
    實體 • The products and services listed on this website are not available in this location.
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    交易 Arrowhead Pharma - ARWR CFD

    33.57
    0.09%
    0.08
    最低: 32.96
    最高: 33.63
    Market Trading Hours* (UTC) Opens on Tuesday at 13:30

    Mon - Fri: 13:30 - 20:00

    • 概括
    • 历史数据
    • 活动
    • 收入报表
    • 资产负债表
    • 现金流
    • 所有权
    交易条件
    价差 0.08
    多头隔夜费

    Long position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 -0.025457 %
    Charges from borrowed part ($-1.02)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		-0.025457%
    空头隔夜费

    Short position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 0.003235 %
    Charges from borrowed part ($0.13)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		0.003235%
    隔夜费时间 21:00 (UTC)
    最小交易量 1
    货币 USD
    保证金 20%
    上市交易所 United States of America
    交易费 0%

    *Information provided by Capital.com

    Arrowhead Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    关键数据
    前收盘价* 33.54
    开仓* 33.23
    1 年变化* -2.03%
    日范围* 32.96 - 33.63
    52 周范围 23.09-48.48
    平均交易量（10 天） 870.44K
    平均交易量（3 个月) 24.66M
    市值 3.59B
    市盈率 -100.00K
    流通股 106.90M
    收入 272.80M
    EPS -1.43
    股息（收益率 %） N/A
    贝塔 0.98
    下一个财报发布日期 Aug 2, 2023

    所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date 平仓 Change Change (%) 開倉 High Low
    May 26, 2023 33.57 0.10 0.30% 33.47 33.75 32.95
    May 25, 2023 33.54 -1.82 -5.15% 35.36 35.37 33.06
    May 24, 2023 35.54 -0.28 -0.78% 35.82 35.97 35.08
    May 23, 2023 36.23 -0.25 -0.69% 36.48 38.51 36.23
    May 22, 2023 36.47 0.20 0.55% 36.27 37.01 36.27
    May 19, 2023 36.22 -0.34 -0.93% 36.56 37.06 36.13
    May 18, 2023 36.23 -0.58 -1.58% 36.81 36.81 35.43
    May 17, 2023 37.07 -0.54 -1.44% 37.61 37.61 36.58
    May 16, 2023 37.59 -1.42 -3.64% 39.01 39.01 37.36
    May 15, 2023 39.83 0.75 1.92% 39.08 40.83 38.86
    May 12, 2023 39.29 0.32 0.82% 38.97 39.40 38.00
    May 11, 2023 40.00 -0.05 -0.12% 40.05 40.42 39.40
    May 10, 2023 40.44 -0.68 -1.65% 41.12 41.12 39.29
    May 9, 2023 40.43 0.57 1.43% 39.86 40.94 39.15
    May 8, 2023 40.41 -0.57 -1.39% 40.98 41.15 39.49
    May 5, 2023 41.30 1.21 3.02% 40.09 42.42 40.09
    May 4, 2023 40.01 0.04 0.10% 39.97 40.41 38.41
    May 3, 2023 40.12 3.00 8.08% 37.12 40.58 36.46
    May 2, 2023 35.28 -0.14 -0.40% 35.42 35.89 34.54
    May 1, 2023 35.70 1.31 3.81% 34.39 35.83 34.31

    Arrowhead Pharma Events

    时间（协调世界时） (UTC) 国家/地区 事件
    Thursday, June 1, 2023

    时间（协调世界时） (UTC)

    13:00

    国家/地区

    US

    事件

    Arrowhead Pharmaceuticals Inc R&D Day
    Arrowhead Pharmaceuticals Inc R&D Day

    Forecast

    -

    Previous

    -
    Wednesday, August 2, 2023

    时间（协调世界时） (UTC)

    10:59

    国家/地区

    US

    事件

    Q3 2023 Arrowhead Pharmaceuticals Inc Earnings Release
    Q3 2023 Arrowhead Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    查看所有活動
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    总收入 243.231 138.287 87.9921 168.796 16.1423
    收入 243.231 138.287 87.9921 168.796 16.1423
    总营业费用 421.738 287.323 181.151 107.605 72.0786
    销售/一般/行政费用，总计 130.095 80.08 51.6649 26.5563 19.1101
    研究与开发 281.222 198.977 123.543 81.0487 52.9685
    Depreciation / Amortization 10.421 8.266 5.943
    异常费用（收入） 0
    Other Operating Expenses, Total 0
    营业收入 -178.507 -149.036 -93.1588 61.1906 -55.9362
    利息收入（费用），非经营净值 5.033 6.12 9.1905 6.95777 1.48066
    Gain (Loss) on Sale of Assets
    其他，净值 0.765 2.07 -0.58252 0 0.00749
    税前净收入 -172.709 -140.846 -84.5508 68.1484 -54.4481
    税后净收入 -176.494 -140.848 -84.5532 67.9749 -54.4505
    少数股东权益 0.431
    未计算非常项目前的净收益 -176.063 -140.848 -84.5532 67.9749 -54.4505
    净收入 -176.063 -140.848 -84.5532 67.9749 -54.4505
    普通股股东可获收益 (不含非经常性项目) -176.063 -140.848 -84.5532 67.9749 -54.4505
    普通股股东可获收益 (含非經常性項目) -176.063 -140.848 -84.5532 67.9749 -54.4505
    摊薄净收入 -176.063 -140.848 -84.5532 67.9749 -54.4505
    摊薄后加权平均股 105.426 103.745 100.722 98.6078 83.6385
    扣除特别项目的每股摊薄盈利 -1.67001 -1.35764 -0.83947 0.68935 -0.65102
    Dividends per Share - Common Stock Primary Issue
    每股正常摊薄盈利 -1.67001 -1.35764 -0.83947 0.68935 -0.65102
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    总收入 146.267 62.546 31.575 32.412 151.805
    收入 146.267 62.546 31.575 32.412 151.805
    总营业费用 98.102 104.68 115.405 105.321 110.252
    销售/一般/行政费用，总计 25.159 22.651 31.624 32.738 33.863
    研究与开发 70.273 79.34 81.121 69.98 73.804
    Depreciation / Amortization 2.67 2.689 2.66 2.603 2.585
    营业收入 48.165 -42.134 -83.83 -72.909 41.553
    利息收入（费用），非经营净值 -0.497 -0.167 1.583 1.24 1.054
    其他，净值 0.008 0.507 0.09 -0.377 1.759
    税前净收入 47.676 -41.794 -82.157 -72.046 44.366
    税后净收入 47.676 -41.811 -85.942 -72.046 44.366
    未计算非常项目前的净收益 48.675 -41.325 -85.511 -72.046 44.366
    净收入 48.675 -41.325 -85.511 -72.046 44.366
    普通股股东可获收益 (不含非经常性项目) 48.675 -41.325 -85.511 -72.046 44.366
    普通股股东可获收益 (含非經常性項目) 48.675 -41.325 -85.511 -72.046 44.366
    摊薄净收入 48.675 -41.325 -85.511 -72.046 44.366
    摊薄后加权平均股 108.143 106.039 105.885 105.753 107.929
    扣除特别项目的每股摊薄盈利 0.4501 -0.38972 -0.80758 -0.68127 0.41107
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    每股正常摊薄盈利 0.4501 -0.38972 -0.80758 -0.68127 0.41107
    少数股东权益 0.999 0.486 0.431
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    流动资产总额 405.299 384.597 322.37 265.247 78.7686
    现金和短期投资 376.396 367.789 315.492 258.704 76.5334
    现金等价物 108.005 184.434 143.583 221.804 30.1332
    短期投资 268.391 183.355 171.909 36.8999 46.4002
    应收账款总额，净额 1.41 10.255 0.84567 0.66136 0.32738
    Accounts Receivable - Trade, Net 1.41 10.255 0.84567 0.66136 0.32738
    Prepaid Expenses 7.289 4.362 4.2509 3.318 1.26772
    Other Current Assets, Total 20.204 2.191 1.78169 2.56344 0.64012
    Total Assets 691.939 710.148 522.504 349.845 111.61
    Property/Plant/Equipment, Total - Net 168.588 66.021 47.0179 23.2149 13.9354
    Property/Plant/Equipment, Total - Gross 200.142 88.885 63.3224 35.2966 23.7408
    Accumulated Depreciation, Total -31.554 -22.864 -16.3044 -12.0816 -9.80536
    Intangibles, Net 11.962 13.663 15.3631 17.0636 18.764
    Other Long Term Assets, Total 0.218 0.272 0.26536 0.14415 0.14192
    Total Current Liabilities 138.85 146.536 40.6814 97.0707 12.365
    Accounts Payable 2.868 9.457 6.82891 7.64992 2.8061
    Accrued Expenses 61.883 26.024 14.5442 11.4606 8.98069
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0.22382
    Other Current Liabilities, Total 74.099 111.055 19.3083 77.9601 0.35434
    Total Liabilities 293.419 301.326 60.7246 105.254 15.8138
    Total Long Term Debt 0 0 0 0 2.1012
    Long Term Debt 0 2.1012
    Capital Lease Obligations
    Minority Interest 19.819 0 -0.55519 -0.55519
    Other Liabilities, Total 134.75 154.79 20.0432 8.73851 1.9028
    Total Equity 398.52 408.822 461.779 244.591 95.7962
    Preferred Stock - Non Redeemable, Net
    Common Stock 0.198 0.197 0.19475 0.18788 0.18088
    Additional Paid-In Capital 1219.21 1053.39 965.41 664.086 582.903
    Retained Earnings (Accumulated Deficit) -820.755 -644.692 -503.844 -419.291 -487.266
    Other Equity, Total -0.136 -0.069 0.01843 -0.39162 -0.02156
    Total Liabilities & Shareholders’ Equity 691.939 710.148 522.504 349.845 111.61
    Total Common Shares Outstanding 105.96 104.327 102.376 95.5063 88.5053
    Total Preferred Shares Outstanding
    Long Term Investments 105.872 245.595 137.487 44.176
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    流动资产总额 574.81 574.999 405.299 432.388 417.63
    现金和短期投资 481.005 501.831 376.396 416.496 401.895
    现金等价物 134.959 202.249 108.005 139.439 86.408
    短期投资 346.046 299.582 268.391 277.057 315.487
    应收账款总额，净额 69.434 39.568 1.41 0.239 1.317
    Accounts Receivable - Trade, Net 69.434 39.568 1.41 0.239 1.317
    Prepaid Expenses 9.935 8.412 7.289 6.761 6.622
    Other Current Assets, Total 14.436 25.188 20.204 8.892 7.796
    Total Assets 891.308 891.489 691.939 751.782 703.575
    Property/Plant/Equipment, Total - Net 226.342 188.969 168.588 140.812 71.267
    Property/Plant/Equipment, Total - Gross 262.414 222.804 200.142 170.147 98.448
    Accumulated Depreciation, Total -36.072 -33.835 -31.554 -29.335 -27.181
    Intangibles, Net 11.112 11.537 11.962 12.387 12.813
    Long Term Investments 78.834 115.774 105.872 165.92 201.59
    Other Long Term Assets, Total 0.21 0.21 0.218 0.275 0.275
    Total Current Liabilities 87.151 122.009 138.85 128.212 138.857
    Accounts Payable 9.556 0.796 2.868 5.894 10.603
    Accrued Expenses 47.756 54.932 61.883 38.03 30.385
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 29.839 66.281 74.099 84.288 97.869
    Total Liabilities 444.536 514.45 293.419 297.855 251.309
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 339.051 373.108 134.75 149.393 112.452
    Total Equity 446.772 377.039 398.52 453.927 452.266
    Common Stock 0.199 0.199 0.198 0.198 0.198
    Additional Paid-In Capital 1260.31 1239.18 1219.21 1189.11 1115.37
    Retained Earnings (Accumulated Deficit) -813.405 -862.08 -820.755 -735.244 -663.198
    Other Equity, Total -0.332 -0.258 -0.136 -0.14 -0.107
    Total Liabilities & Shareholders’ Equity 891.308 891.489 691.939 751.782 703.575
    Total Common Shares Outstanding 106.869 106.14 105.96 105.795 105.702
    Minority Interest 18.334 19.333 19.819 20.25
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    净收入/起跑线 -176.494 -140.848 -84.5532 67.9749 -54.4505
    经营活动产生的现金 -136.131 171.224 -95.3916 173.035 -47.2234
    经营活动产生的现金 10.421 8.267 5.94226 4.43914 4.69928
    非现金物品 128.235 76.939 43.9083 13.4624 8.40554
    Cash Taxes Paid 0.002 0.002 -0.10344 0.3024 0.0024
    已付现金利息 0 0 0 0.02744 0.17338
    营运资金的变化 -98.293 226.866 -60.6889 87.1585 -5.87776
    投资活动产生的现金 -5.417 -141.678 -240.778 -47.746 -7.43496
    资本支出 -52.777 -23.567 -11.9517 -12.0012 -1.42125
    其他投资现金流量项目，总计 47.36 -118.111 -228.826 -35.7448 -6.01371
    融资活动产生的现金 65.186 11.305 257.948 66.382 59.953
    融资现金流项目 60 0 0 -0.05467
    股票的发行（报废），净额 5.186 11.305 257.948 68.7971 60.2162
    债务的发行（退还），净额 0 -2.41515 -0.20851
    现金净变化 -76.429 40.851 -78.2215 191.671 5.29465
    外汇效应 -0.067
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line 5.865 -41.811 -176.494 -90.552 -18.506
    Cash From Operating Activities -107.187 -75.516 -136.131 -67.464 1.383
    Cash From Operating Activities 5.358 2.689 10.421 7.761 5.167
    Non-Cash Items 47.826 22.929 128.235 99.465 62.789
    Changes in Working Capital -166.236 -59.323 -98.293 -84.138 -48.067
    Cash From Investing Activities -116.759 -80.694 -5.417 -41.862 -103.14
    Capital Expenditures -66.225 -38.911 -52.777 -20.066 -10.53
    Other Investing Cash Flow Items, Total -50.534 -41.783 47.36 -21.796 -92.61
    Cash From Financing Activities 251.096 250.576 65.186 64.331 3.731
    Issuance (Retirement) of Stock, Net 1.096 0.576 5.186 4.331 3.731
    Net Change in Cash 26.954 94.244 -76.429 -44.995 -98.026
    Cash Taxes Paid 0 0
    Cash Interest Paid 0 0
    Financing Cash Flow Items 250 250 60 60
    Foreign Exchange Effects -0.196 -0.122 -0.067
    投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
    BlackRock Institutional Trust Company, N.A. Investment Advisor 10.8288 11575992 32030 2023-03-31 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.9771 10665598 401699 2023-03-31 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 5.5217 5902768 -67576 2023-03-31 LOW
    Anzalone (Christopher Richard) Individual Investor 3.4805 3720714 0 2023-05-04 MED
    Invesco Advisers, Inc. Investment Advisor 1.9738 2109950 4029 2023-03-31 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9444 2078527 104976 2023-03-31 LOW
    JP Morgan Asset Management Investment Advisor 1.7531 1874095 281642 2023-03-31 LOW
    Avidity Partners Management LP Hedge Fund 1.6289 1741300 366300 2023-03-31 HIGH
    Rokos Capital Management LLP Hedge Fund 1.5677 1675921 1274999 2023-03-31 HIGH
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.3892 1485073 544004 2022-12-31 LOW
    Fidelity Management & Research Company LLC Investment Advisor 1.2846 1373247 -616286 2023-03-31 LOW
    Credit Suisse Asset Management Investment Advisor/Hedge Fund 1.153 1232545 8305 2023-03-31 LOW
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 1.092 1167363 22669 2023-03-31 LOW
    Charles Schwab Investment Management, Inc. Investment Advisor 1.0829 1157575 19132 2023-03-31 LOW
    First Manhattan Co. LLC Investment Advisor 0.9594 1025654 0 2023-03-31 LOW
    Aquilo Capital Management, LLC Investment Advisor/Hedge Fund 0.9527 1018474 -85041 2023-03-31
    Millennium Management LLC Hedge Fund 0.9068 969394 393770 2023-03-31 HIGH
    JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 0.878 938585 1607 2023-03-31 LOW
    Citadel Advisors LLC Hedge Fund 0.7935 848305 204332 2023-03-31 HIGH
    Western Financial Corporation Investment Advisor 0.7674 820320 0 2023-03-31 LOW

    为什么选择 Capital.com？让我们的数字来说话。

    Capital.com Group

    530K+

    交易者

    87K+

    每月活跃客户

    $46M+

    每月投资额

    $31M+

    每月提取金额

    交易计算器

    如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。

    交易佣金
    0
    • 1:1
    杠杆
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    投资
    交易规模（杠杆 x 投资）：
    開倉

    平仓

    做空 做多
    過去的表現並不是未來結果的可靠指標
    盈利/盈利/亏损

    Arrowhead Pharma Company profile

    关于 Arrowhead Pharmaceuticals Inc

    Arrowhead Pharmaceuticals, Inc.开发的药物通过抑制导致疾病的基因来治疗难治性疾病。 公司使用核糖核酸（RNA）化学组合和给药方式，公司的疗法触发了RNA干扰机制，以诱导快速、深入和持久地击倒目标基因。 公司专注于开发具有遗传基础的疾病的药物，其特点是一种或多种蛋白质的过度生产。 公司的产品线包括治疗高甘油三酯血症的ARO-APOC3，治疗血脂异常的ARO-ANG3，治疗肝病的ARO-HSD，治疗囊性纤维化的ARO-ENaC，治疗肾细胞癌的ARO-HIF2。 ARO-DUX4用于面肌萎缩症，ARO-LUNG2用于慢性阻塞性肺病，ARO-COV用于引起COVID-19的冠状病毒和其他未来可能的肺部传播病原体。

    Industry: Bio Therapeutic Drugs

    177 E Colorado Blvd
    Suite 700
    PASADENA
    CALIFORNIA 91105
    US

    收入报表

    • Annual
    • Quarterly

    人们也观看

    US100

    14,346.30 Price
    +0.140% 1D Chg, %
    多头隔夜费 -0.0255%
    空头隔夜费 0.0032%
    隔夜费时间 21:00 (UTC)
    价差 1.8

    Oil - Crude

    72.83 Price
    -0.150% 1D Chg, %
    多头隔夜费 -0.0146%
    空头隔夜费 -0.0073%
    隔夜费时间 21:00 (UTC)
    价差 0.03

    XRP/USD

    0.50 Price
    +3.370% 1D Chg, %
    多头隔夜费 -0.0753%
    空头隔夜费 0.0069%
    隔夜费时间 21:00 (UTC)
    价差 0.00414

    BTC/USD

    27,667.30 Price
    +0.310% 1D Chg, %
    多头隔夜费 -0.0616%
    空头隔夜费 0.0137%
    隔夜费时间 21:00 (UTC)
    价差 60.00

    还在找一位您可以信任的经纪商吗？

    加入成为全球530,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

    1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易